Clinical Profile of Oprozomib and Ixazomib in Relapsed or Refractory MM


Clinical Profile of Oprozomib and Ixazomib in Relapsed or Refractory MM
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Kumar S et al. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (pts) with previously untreated multiple myeloma (MM): Phase 2 study results. Proc ASH 2014;Abstract 82.

Vij R et al. Clinical profile of single-agent oprozomib in patients (Pts) with multiple myeloma (MM): Updated results from a multicenter, open-label, dose escalation Phase 1b/2 study. Proc ASH 2014;Abstract 34.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.